MAP
LKFT

Madison Avenue Partners’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Madison Avenue Partners’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74M Buy
2,465,179
+252,010
+11% +$8.34M 3.22% 11
2025
Q4 		$72.4M Buy
2,213,169
+17,394
+0.8% +$562K 3.11% 11
2025
Q3 		$76.1M Buy
2,195,775
+318,764
+17% +$10.2M 4.54% 8
2025
Q2 		$52.5M Buy
+1,877,011
New +$50.3M 3.51% 10

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madison Avenue Partners's LKFT Position: Q1 2026 in Review

Madison Avenue Partners increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 11% in Q1 2026, buying an estimated $8.34M and bringing the position to 2,465,179 shares worth $74M. The position accounts for 3.22% of the portfolio, ranked #11.

Madison Avenue Partners first reported a position in LKFT in Q2 2025 and has held it in 4 quarters since. The position peaked at $76.1M in Q3 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Madison Avenue Partners held 2,465,179 shares of Lakefront Biotherapeutics American Depositary Shares worth $74M as of Q1 2026.
  • Madison Avenue Partners bought 252,010 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $8.34M.
  • Lakefront Biotherapeutics American Depositary Shares made up 3.22% of Madison Avenue Partners's portfolio in Q1 2026, its #11 holding.
  • Madison Avenue Partners first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2025 and has held it in 4 quarters since.
  • Madison Avenue Partners's Lakefront Biotherapeutics American Depositary Shares position peaked at $76.1M in Q3 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Madison Avenue Partners's 13F filing for Q1 2026, filed 15 May 2026.